C
7.15
-0.06 (-0.83%)
| Previous Close | 7.21 |
| Open | 7.28 |
| Volume | 127,720 |
| Avg. Volume (3M) | 253,798 |
| Market Cap | 62,224,448 |
| Price / Book | 1.58 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -200.58% |
| Operating Margin (TTM) | -276.55% |
| Diluted EPS (TTM) | -2.17 |
| Quarterly Revenue Growth (YOY) | -18.30% |
| Current Ratio (MRQ) | 9.78 |
| Operating Cash Flow (TTM) | -19.00 M |
| Levered Free Cash Flow (TTM) | -11.99 M |
| Return on Assets (TTM) | -56.19% |
| Return on Equity (TTM) | -93.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | CervoMed Inc. | Bearish | Bearish |
AIStockmoo Score
0.0
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 1.0 |
| Average | 0.00 |
|
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 33.38% |
| % Held by Institutions | 26.31% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Perigon Wealth Management, Llc | 31 Mar 2025 | 18,206 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Chardan Capital, 109.79%) | Buy |
| Median | 12.50 (74.83%) | |
| Low | 10.00 (D. Boral Capital, 39.86%) | Buy |
| Average | 12.50 (74.83%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 8.29 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 11 Jun 2025 | 10.00 (39.86%) | Buy | 7.47 |
| 13 May 2025 | 10.00 (39.86%) | Buy | 8.70 | |
| Chardan Capital | 12 May 2025 | 15.00 (109.79%) | Buy | 9.10 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jul 2025 | Announcement | CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025 |
| 10 Jun 2025 | Announcement | CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization |
| 12 May 2025 | Announcement | CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates |
| 07 May 2025 | Announcement | CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |